Google DeepMind Adds AI Drug Discovery Tools to Antigravity Platform

In a demonstration focused on non-small cell lung cancer, an AI agent analyzed existing compounds and proposed new molecular structures in approximately one hour, compared with the several days the process would typically take, according to the company.

Google DeepMind has introduced a set of AI-powered drug discovery tools for its Antigravity platform, enabling researchers to analyze chemical compounds, predict drug potency, and generate new molecule designs for laboratory testing.

In a demonstration focused on non-small cell lung cancer, an AI agent analyzed existing compounds and proposed new molecular structures in approximately one hour, compared with the several days the process would typically take, according to the company.

The demonstration used crizotinib and lorlatinib, two drugs prescribed for certain forms of non-small cell lung cancer. The AI agent searched scientific literature and patents, retrieved records on thousands of compounds, and filtered out irrelevant entries, including solvents.

Researchers then instructed the agent to compare pairs of compounds that differed by a single structural modification. The analysis found that introducing a bond to form a ring generally increased molecular rigidity and potency.

Using these findings, the agent developed predictive models to estimate compound potency and proposed new ring-shaped molecules, along with potential synthesis methods for laboratory testing.

Google DeepMind said the demonstration workflow took about an hour. However, the company emphasized that the proposed molecular designs require experimental validation, noting that every proposed design must be synthesized and tested in a laboratory.

The tools are accessible through the Science plug-in within the Google Antigravity application.

As part of the rollout, Google is offering six months of free access to its highest Antigravity usage tier for 10,000 scientists, subject to eligibility and selection.

AI Drug Discovery Partnerships Expand

The launch comes amid growing investment and collaboration in AI-driven drug discovery.

In May 2026, Isomorphic Labs, which originated from Google DeepMind, raised $2.1 billion in Series B funding to expand its AI-based drug discovery platform. The company uses predictive and generative AI to model molecular interactions and advance its drug development pipeline.

In September 2026, Iambic and AbbVie announced a multiyear collaboration to develop small-molecule drugs across neuroscience, oncology, and immunology. The partnership uses Iambic's Enchant v3 model, which analyzes clinical and biomedical data to predict drug properties, alongside automated chemistry and biology experiments.

Earlier, in June 2026, Owkin and Sanofi expanded their AI partnership to develop AI agents for drug research and development. Under a five-year licensing agreement, Owkin will deploy the agents through its K Pro platform, which combines patient data and specialized AI models to support drug development from early discovery through clinical development.

Stay tuned for more such updates on Digital Health News